跳至主要内容
临床试验/ACTRN12614000821695
ACTRN12614000821695已完成1 期

Study to assess the safety of hypofractionated radiotherapy with concurrent carboplatin and paclitaxel in palliative management of esophageal cancers.

Calvary Mater Newcastle0 个研究点目标入组 18 人开始时间: 2014年8月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1.Histologically proven squamous cell carcinoma or adenocarcinoma of the esophagus or gastro-esophageal junction.
  • 2.Symptomatic with Mellow dysphagia score of at least 1.
  • 3.Patients not considered amenable to curative surgery or radical chemoradiotherapy due to either patient-related factors or advanced esophageal cancer stage (locoregional lymphadenopathy and/or low volume metastatic disease).
  • 4. ECOG performance status 0-2.
  • 5. No contraindication to receiving weekly carboplatin or paclitaxel chemotherapy including adequate bone marrow function.
  • 6. Above 18 years old.

排除标准

  • 1.Previous thoracic radiotherapy.
  • 2.Tracheo-esophageal fistula.
  • 3.Esophageal stents in situ.
  • 4.Previous chemotherapy for esophageal cancer.
  • 5.Presence of bulky or organ-threatening metastatic disease requiring immediate higher dose chemotherapy.
  • 6.Pregnant patients.

研究者

相似试验